Drug intelligence / Profile preview

diclofenac + omeprazole

Development stage
Unknown
Lead developer
Bago
Modality
Small Molecules
Administration
Oral
01

Overview

Diclofenac + omeprazole is a fixed-dose combination of two drugs. Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) that works by inhibiting cyclooxygenase-1 and -2 (COX-1 and COX-2), enzymes responsible for the synthesis of prostaglandins involved in pain, inflammation, and fever. Omeprazole is a proton pump inhibitor (PPI) that irreversibly inhibits the H+/K+-ATPase enzyme system on gastric parietal cells, thereby suppressing gastric acid secretion. The combination is primarily used to manage pain and inflammation in conditions such as rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, acute musculoskeletal pain, postoperative pain, migraines, and other painful conditions where NSAID therapy is indicated but there is also a need to reduce the risk of NSAID-induced gastrointestinal ulcers or mucosal damage[1][3][5]. This combination provides effective analgesia while protecting against gastrointestinal side effects associated with long-term NSAID use.

Brand names
Mobinac ODiotopDicnak O
Other names
diclofenac/omeprazole
02

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)ATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on diclofenac + omeprazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on diclofenac + omeprazole.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call